Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...

In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...

Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the ...

Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device. Joseph Mikhael, MD, MEd, professor in the Applied Cancer Research and ...

KOMET-007 shows ziftomenib plus venetoclax/azacitidine drives deep MRD-negative remissions in R/R AML, with manageable ...

Dr. Monty Pal summarizes his practical first-line treatment algorithm for advanced renal cell carcinoma (RCC), highlighting ...

Approval addresses the ~60% of HR+/HER2− advanced cases of patients with PIK3CA wild-type disease who are ineligible for PI3Kα-selective inhibitors. VIKTORIA-1 met primary PFS end points with ...

OptiTROP-Lung06 demonstrated statistically significant, clinically meaningful PFS improvement for sac-TMT plus pembrolizumab versus pembrolizumab plus pemetrexed/platinum in first-line driver-negative ...